Fig. 3.
(A) ERK1/2 phosphorylation in FPS cells in response to treatment with 100 nM PGE2 or 100 nM PGF2α for 0, 2, 5, 10 and 20 min. ERK1/2 phosphorylation in FPS cells in response to treatment with 100 nM PGE2 (B) or 100 nM PGF2α (C) for 10 min in the presence/absence of the FP receptor antagonist AL8810 (50 μM), EP2 receptor antagonist (AH6809; 10 μM), EP4 receptor antagonist (ONOAE2227; 1 μM) or chemical inhibitors of phospholipase Cβ (U73122, 10 μM), protein kinase A (4C3MQ, 1 μM), protein kinase C (GF109203x, 10 μM), EGFR kinase (AG1478, 200 nM) or ERK1/2 kinase (PD98059, 50 μM). Data are presented as mean ± S.E.M. b is significantly different from a and c is significantly different from a and b; P < 0.05.